UK markets closed

Black Diamond Therapeutics, Inc. (BDTX)

NasdaqGS - NasdaqGS Delayed price. Currency in USD
Add to watchlist
5.89+0.78 (+15.26%)
At close: 04:00PM EDT
5.87 -0.02 (-0.34%)
After hours: 07:46PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 304.62M
Enterprise value 198.52M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)2.61
Enterprise value/revenue N/A
Enterprise value/EBITDA -2.31

Trading information

Stock price history

Beta (5Y monthly) 2.64
52-week change 3270.44%
S&P500 52-week change 322.36%
52-week high 36.85
52-week low 31.43
50-day moving average 34.93
200-day moving average 33.49

Share statistics

Avg vol (3-month) 3650.02k
Avg vol (10-day) 3589.59k
Shares outstanding 551.72M
Implied shares outstanding 651.72M
Float 836.16M
% held by insiders 12.57%
% held by institutions 192.19%
Shares short (15 Apr 2024) 41.76M
Short ratio (15 Apr 2024) 43.52
Short % of float (15 Apr 2024) 45.42%
Short % of shares outstanding (15 Apr 2024) 43.40%
Shares short (prior month 15 Mar 2024) 41.81M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-34.33%
Return on equity (ttm)-70.94%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -86.02M
Net income avi to common (ttm)-82.44M
Diluted EPS (ttm)-1.88
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)131.4M
Total cash per share (mrq)2.54
Total debt (mrq)25.3M
Total debt/equity (mrq)21.67%
Current ratio (mrq)6.82
Book value per share (mrq)2.26

Cash flow statement

Operating cash flow (ttm)-66.72M
Levered free cash flow (ttm)-37.65M